Clearside biomedical, inc. (CLSD)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17
Operating activities
Net loss

-18,277

-30,770

-49,312

-66,648

-81,615

-82,818

0

0

0

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation

203

211

208

202

195

189

188

189

199

182

0

0

0

Share-based compensation expense

4,366

4,612

4,635

4,951

4,894

4,785

4,567

4,170

3,750

3,364

0

0

0

Non-cash interest expense

127

163

188

187

151

154

159

166

208

211

0

0

0

Accretion of debt discount

73

67

63

64

78

112

149

186

208

212

0

0

0

Amortization and accretion on available-for-sale investments, net

-

115

349

619

808

748

551

305

92

31

0

0

0

Changes in operating assets and liabilities:
Prepaid expenses and other current assets

2,045

558

-1,752

-672

-1,644

505

2,394

1,424

-859

833

0

0

0

Other assets and liabilities

0

-

-

-

0

-

-

-

-

-

-

-

-

Other assets and liabilities

-

-

-

-

-

-

-

0

0

-

-

-

-

Other assets

-

-

-

-

-

-

-

-

-

-

0

0

0

Accounts payable and accrued liabilities

-6,654

-5,582

-10,533

-5,656

-669

-314

5,575

5,369

4,184

4,715

0

0

0

Deferred revenue

-

-

-

-

-

-

-

-

-

-

0

0

0

Deferred rent

-

-

-

-

-

-

-

-

81

-

0

0

0

Net cash used in operating activities

-17,218

-27,068

-53,016

-66,688

-76,200

-79,200

0

0

0

-

-

-

-

Investing activities
Maturities of available-for-sale investments

-

32,950

49,450

77,550

86,450

76,470

75,431

75,403

82,538

68,543

0

0

0

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

0

Purchase of available-for-sale investments

-

-

-

-

-

-

-

-

0

-

0

0

0

Acquisition of property and equipment

62

25

0

0

0

-

-

-

-

306

0

0

0

Net cash (used in) provided by investing activities

1,938

32,925

49,366

49,741

14,927

-3,760

0

0

0

-

-

-

-

Financing activities
Proceeds from at-the-market sales agreement, net of issuance costs

0

-

-

-

0

-

-

-

-

-

-

-

-

Net cash provided by (used in) investing activities

-

-

-

-

-

-

-

-

-

-

-

-

0

Proceeds from follow-on public offering, net of issuance costs

-

-

-

-

-

-

0

0

0

-

0

0

0

Proceeds from exercise of stock options

-

7

38

33

229

465

476

477

400

239

0

0

0

Principal payments made on long-term debt

-

-

-

-

-

8,300

0

0

0

-

-

-

-

Net cash provided by financing activities

3,260

8,695

10,360

7,936

9,389

81,779

0

0

0

-

-

-

-

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

0

Net (decrease) increase in cash, cash equivalents and restricted cash

-12,020

14,552

6,710

-9,011

-51,884

-1,181

-448

18,510

61,845

-25,600

0

0

0

Supplemental disclosure
Tenant improvements paid by landlord

-

-

-

-

-

-

-

-

-

637

0

0

0